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DISEASE MODIFYING THERAPY FOR 
MULTIPLE SYSTEM ATROPHY – PARKINSONIAN TYPE 
SEAN DWYER 
ABSTRACT 
BACKGROUND 
Multiple System Atrophy –Parkinsonian Type (MSA-P) is a rare, rapidly progressive 
neurodegenerative disease without any current treatment. Recent research has increased 
the understanding of brain iron accumulation and its association with neurodegenerative 
synucleinopathies, like MSA-P. Because of this improved understanding of the disease 
process, there is potential for new therapies that could benefit patients with MSA-P. 
Unfortunately, many attempts at finding a new and effective treatments for MSA-P have 
been unsuccessful. Two drugs that have shown potential in neurodegenerative 
synucleinopathies associated with brain iron accumulation are iron chelators 
(Deferiprone) and tyrosine kinase inhibitors (Nilotinib.)  
METHODS 
The proposed study is a multicenter, double blind, randomized control study of Nilotinib 
and Deferiprone for the treatment of MSA-P. There will be two treatment arms; Nilotinib 
and a placebo group vs. Nilotinib and Deferiprone. There will be a 24 week treatment 
phase, followed by a 24 week wash-out phase. All patients will have a baseline 
evaluation including: a full neurological exam with rating scales (UMSARS, UPDRS, 
SCOPA, and MOCA) to assess motor and non-motor symptoms of MSA-P. Lab and 
imaging data will include CBC, CMP, serum iron panel, CSF iron panel and brain SWI-
  vi 
MR scans. Neurological exams and rating scales will be assessed every four weeks 
while imaging and laboratory data will be assessed at baseline (week 0) at the end 
of the intervention phase (week 24) and at the end of the follow-up phase (week 
48). 
CONCLUSIONS 
Deferiprone and Nilotinib when used together will have a synergistic impact on the 
symptoms of MSA-P and will be more effective when used together versus when 
they are used individually.  
SIGNIFICANCE 
Patients with MSA-P have shortened life expectancy as well as severely diminished 
quality of life due to rapidly progressive neurodegeneration. This trial aims to 
implementing evidence based treatment for MSA-P that could potentially improve life 
expectancy as well as quality of life in this patient population.  
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INTRODUCTION 
Background 
Multiple system atrophy (MSA) is a rare neurological disorder with both motor and non-
motor dysfunction. MSA-P is a subtype of MSA with predominant Parkinson's disease-
like symptoms, such as slowness of movement, muscle rigidity and poor balance. 2 In 
addition to Parkinsonian symptoms, the disease also impairs the body's autonomic 
functions, including blood pressure, heart rate, bladder function and digestion as well as 
many The classification of MSA unifies multiple neurodegenerative disorders formerly 
called Shy-Drager syndrome, striatonigral degeneration, and olivopontocerebellar 
atrophy. Both Parkinson Disease (PD) and Multiple System Atrophy (MSA) are alpha-
synucleinopathies that are characterized by accumulation of alpha-synuclein proteins in 
brain cells, causing dysfunction and cell death.3 PD and MSA are defined by the cells in 
which the alpha-synuclein accumulates.4 Alpha synuclein pathology is more pervasive 
and varied in MSA than it is in PD. In PD there is accumulation of a-syn in the 
dopaminergic neurons of the substantia nigra, and in MSA there is accumulation of a-syn 
in the neurons and oligodendrocytes of the substantia nigra, striatum, 
olivopontocerebellar structures and spinal cord.5 Currently, there is no available treatment 
for MSA, and patients with MSA typically do not respond well to treatment with 
Carbidopa/Levodopa.  Brain cells of patients with synucleinopathies have been shown to 
have abnormally high activation of c-abl cell receptors. These receptors activate the 
production of a-syn and are believed to be a major contributor to the pathology of 
synucleinopathies. Nilotinib, a c-abl tyrosine kinase inhibitor that is FDA approved for 
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the treatment of chronic myeloid leukemia has recently been shown to induce autophagy 
in brain cells and remove alpha-synuclein, leading to drastic improvements in motor 
function.6    
There is a relationship between the accumulations of iron in brain cells of patients 
with alpha-synucleinopathies. For both PD and MSA there are increased levels of iron in 
the substantia nigra and olivopontocerebellar structures, respectively. 55 In PD iron and 
ferroportin are increased in the dopaminergic neurons of the Substantia nigra. In MSA 
increased total iron and ferritin concentration are increased in the SN and also in the 
striatum, pons, cerebellum, and spinal cord.4 These regional differences are also 
supported by SWI-MR that is sensitive to intracellular iron concentrations.7 
Unfortunately, the mechanisms of iron dysregulation in MSA and PD are unknown, but 
increased iron concentration found in these diseases is likely a major contributor to the 
pathology of a-syn accumulation. Many studies indicate that the oxidative stress from the 
iron contributes to the mis-folding of a-Syn.8 9 It has also been suggested that DNA 
damage secondary to the oxidative stress caused by iron contributes to c-abl activation 
further aggravating a-syn accumulation.10 Deferiprone, an iron chelator that crosses the 
blood-brain barrier (BBB) has been proven in clinical trials to decrease iron concentration 
in brain cells and improve motor function in patients with neurodegenerative diseases 
with iron accumulation.4  Any novel approach to the treatment of MSA-P must take into 
consideration both iron and a-syn and their roles in the pathology of MSA-P.  
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Statement of the Problem 
There is currently no approved treatment that can delay or reverse the 
neurodegeneration of MSA.11 Multiple recent clinical trials of potential therapies 
including: Rasagaline, Rifampicin, Lithium, growth hormone, and minocycline have 
all shown no benefit over a placebo.11 Fortunately, recent breakthroughs in the 
treatment of PD, a closely related synucleinopathy, have the potential to benefit 
patients suffering from MSA. However, when the treatment is stopped, the patient’s 
motor function quickly regressed back to their baseline despite restarting L-Dopa 
treatment.6  A recent small-scale open-label trial has shown that Nilotinib treatment 
made drastic improvement in the motor function of patients with Parkinson 
Disease, due to its ability to remove alpha-synuclein (a-Syn) protein from 
dopaminergic neurons.6 Additionally, Deferiprone (an iron chelator that crosses the 
blood-brain barrier) has shown mild to moderate improvements in the treatment of 
neurodegenerative diseases with iron accumulation, and has been proven a safe 
therapy in this patient population.4 
 
Hypothesis 
Combination therapy with Nilotinib and Deferiprone will improve the motor and 
non-motor symptoms caused by a-syn and iron accumulation in patients with MSA-
P.  
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Objectives and specific aims  
Given that iron and alpha-synuclein are both found in brain cells of patients with MSA, 
the purpose of this study is to see if the combination of Deferiprone and Nilotinib would 
improve the treatment outcomes for patients with MSA. Because these drugs target 
separate etiologies of MSA (Deferiprone removes iron from brain cells and Nilotinib 
removes a-Syn), then they should be more effective when used in combination versus 
when they are used separately. 
 
1. Nilotinib and Deferiprone will provide motor and non-motor benefits to patients with 
MSA-P similar to the benefits demonstrated in PD patients. 
2. The addition of Deferiprone to Nilotinib will delay the regression of motor and non-
motor symptoms after Nilotinib treatment has been stopped.   
The parameters that will be measured are: 1) Unified Multiple System Atrophy Rating 
Scale (UMSARS) to assess motor function of the patients,1  2) The Scales for Outcomes 
in Parkinson’s disease – Autonomic (SCOPA)12 to assess autonomic dysfunction, and 3) 
the Montreal Cognitive Assessment (MOCA) to assess for Dementia13, and the unified 
Parkinson’s Disease Rating Scale (UPDRS).  14 
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REVIEW OF THE LITERATURE 
Overview 
Multiple system atrophy (MSA) is a rapidly progressive and fatal neurodegenerative 
disease of unknown etiology.  Currently, the treatment is merely supportive as there are 
no known pharmacological therapies that have been proven to effectively reverse, halt, or 
even slow down the neurodegeneration.  MSA is classified as an alpha-synucleinopathy 
along with Parkinson Disease (PD) and Dementia with Lewy bodies (DLB). Alpha-
synucleinopathies are brain diseases that share a common pathophysiology of 
neurodegeneration that may be related to an accumulation of alpha-synuclein (a-syn) 
proteins in the neurons. Each of the synucleinopathies are differentiated by the cells in 
which the a-syn accumulates. In PD there is accumulation in the dopaminergic neurons of 
the substantia nigra leading to a reduction in dopamine production. In DLB there is 
accumulation in the cerebral cortex and basal nucleus leading to reduced acetyl-choline 
and in MSA there is accumulation in oligodendrocytes and glial cells of the 
olivopontocerebellar structures and spinal cord. 5 A hallmark of MSA are glial 
cytoplasmic inclusions (GCIs), which are clumps of fibrillized a-syn proteins that form 
within the glial cells of the brain.  GCIs represent the most consistent and frequent 
pathological lesion in MSA, but a-synuclein can also accumulate in other cellular 
locations and cell types. These include the nuclei of oligodendrocytes to form glial 
nuclear inclusions (GNIs), neuronal cytoplasmic inclusions (NCIs), and neuronal nuclear 
inclusions (NNIs).15 16 
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For years one leading theory of a-syn accumulation has been the “prionoid” 
hypothesis. Likening MSA to Alzheimer’s disease, a neurodegenerative disease also 
related to accumulation of Tau proteins. Although tau and a-syn proteins differ 
significantly it was assumed that they could share a common pathway leading to 
neurodegeneration.17 Unfortunately, large scale randomized clinical trials of anti-prion 
medications have not shown any benefits when given to patients with MSA.18 
Recent research into why a-syn accumulates in the neurons of patients suffering 
from MSA and other synucleinopathies like PD and DLB have suggested that iron 
accumulation may play a role in the pathophysiology.  There is a relationship between the 
accumulations of iron and a-syn in brain cells of patients with PD and MSA. For both PD 
and MSA there are increased levels of iron in the substantia nigra and 
olivopontocerebellar structures, respectively. 19  
Recent publications of safety and efficacy trials of c-abl tyrosine kinase inhibitors 
have shown promise for a possible treatment of synucleinopathies. The cell receptor c-abl 
it highly active in the brains of patients with PD. The c-abl receptor regulates several 
cellular processes and is believed to be contribute to a-syn accumulation when activated. 
20 Nilotinib, a c-abl tyrosine kinase inhibitor that is FDA approved for the treatment of 
chronic myeloid leukemia has been shown to induce autophagy in brain cells and remove 
alpha-synuclein, leading to drastic improvements in motor function6.   However, when 
the treatment is stopped, the patient’s motor function regressed back to their baseline 
despite restarting L-Dopa treatment. 21 
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There is a growing body of evidence to support irons role in neurodegenerative 
diseases. Many studies indicate that the oxidative stress from the iron contributes to the 
activation of c-abl and the mis-folding of a-Syn. 9 8 This suggests that even though 
Nilotinib may be able to remove a-syn from cells, if the iron remains in the cell it will 
incite a-syn to re-accumulate. This mechanism may explain why the effects of the 
Nilotinib are temporary.   Deferiprone, an iron chelator that crosses the blood-brain 
barrier (BBB) has been proven in clinical trials to decrease iron concentration in brain 
cells and improve motor function in patients with neurodegenerative diseases with iron 
accumulation. 22 It is the objective of this thesis that the combination of Deferiprone with 
Nilotinib would be more effective in treating MSA. When these drugs are used in 
adjuvant therapy they may be able to remove the iron and a-syn from the cytoplasm and 
prevent them from re-accumulating.  
Neurodegeneration resulting from MSA can effect several structures of the brain 
and spinal cord23.  The term MSA was introduced in 1996 in order to unify several pre-
existing clinical neurodegenerative syndromes, such as olivopontocerebellar atrophy, 
striatonigral degeneration and Shy-Drager syndrome. Patients with MSA may present 
with a variety of sign and symptoms including parkinsonian features; cerebellar, 
autonomic, and urogenital dysfunction; and corticospinal disorders. MSA is categorized 
based on the predominate symptoms.  MSA-P is characterized by parkinsonian 
symptoms, MSA-C is characterized by cerebellar ataxia, and MSA-A is characterized by 
autonomic dysfunction. In addition to the predominant symptoms, additional red flag 
symptoms that suggest a diagnosis of MSA include: orthostatic hypotension, erectile 
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dysfunction, orofacial dystonia, dysphonia, dysarthria, cold hands and feet and contracted 
hands and feet. Recent research suggests that rapid eye movement behavioral disorder 
(RBD) could be an early symptom of synucleinopathies. RBD is characterized by 
abnormal movements during REM sleep. Normally, there is no movement during REM 
sleep, but patients with RBD may act-out or vocalize what they are dreaming about 
during the REM phase. 24 
 
 
The variety and severity of presentations of MSA make the diagnosis of MSA 
very challenging, especially in the early stages. The diagnoses categories are separated 
into possible, probable and definitive MSA as outlines in the table below.  
 
 
8 
dysfunction, orofacial dystonia, dysphonia, dysarthria, cold hands and feet and contracted 
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abnormal movements during REM sleep. Normally, there is no movement during REM 
sleep, but patients with RBD may act-out or vocalize what they are dreaming about 
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Figure adapted from Towards transitional therapies for multiple system atrophy.  
 
 
The variety and severity of presentations of MSA make the diagnosis of MSA 
very challenging, especially in the early stages. The diagnoses categories are separated 
into possible, probable and definitive MSA as outlines in the table below.  
Category                                    Definition 
Possible MSA x Parkinsonism or cerebellar syndrome  
x And at least 1 feature of autonomic or urogenital 
dysfunction  
Probable MSA x Parkinsonism or cerebellar syndrome that is poorly 
responsive to levodopa  
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 Autonomic failure involving urinary dysfunction  
Definitive MSA  Pathologically confirmed by presence of high density 
GCIs in association with degenerative changes in 
striatonigral and olivopontocerebellar pathways 
(postmortem) 
Table adapted from: Medscape: Multiple System Atrophy 
MSA can be evaluated clinically by using validated rating scales that assess the 
various symptoms and presentations associated with the disease. The Unified Multiple 
System Atrophy Rating Scale (UMSARS) is used to assess motor function of the 
patients,1 Scales for Outcomes in Parkinson’s disease – Autonomic (SCOPA) to assess 
autonomic dysfunction12, and the Montreal Cognitive Assessment (MOCA) to assess for 
Dementia.13 In addition to clinical assessment of MSA neuroimaging is helpful in making 
a diagnoses. MRI evaluations of MSA patients will typically reveal olivopontocerebellar 
atrophy (OPCA), atrophy of the brainstem, and putaminal lesions of striatonigral 
degeneration. These findings in the absence of signs of other lesions, vascular damage, or 
multiple old infarcts is indicative of MSA.25 A PET scan of patients with MSA may show 
reduced uptake in the putamen as well as reduced cerebellar glucose uptake.9   The only 
definitive way to diagnose MSA is to correlate clinical and histologic findings. Histologic 
findings of MSA consist of high density GCIs in structures of the brain demonstrating 
degeneration. Most common structures affected include: Putamen, caudate nucleus, 
substantia nigra, and cerebellar purkinje fibers.16   
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MSA is a rare disease with prevalence of 3.4-4.9 cases per 100,000 population 
and estimated mean incidence of .6-.7 cases per 100,000 person years.26 Though the 
prevalence may actually be higher than reported due to misdiagnoses. The disease is 
more common in males, accounting for around 55% of reported cases. However, male 
impotence may make diagnoses of MSA easier in males and lead to more diagnoses in 
male patients. The average age of onset is 54 and the median survival rate is only 6.2-9.5 
years following diagnosis. An older age of onset has been associated with shorter 
duration of survival. Compared to PD, patients with MSA are also at an increased risk of 
severe depression and report lower health related quality of life scores.27 The most 
common terminal conditions associated with MSA are pneumonia, sudden death, and 
sepsis secondary to urinary tract infection (UTI). More than half of patients with MSA 
will experience recurrent UTIs related to autonomic urinary dysfunction.      
A case control study performed in 1989 revealed several risk factors related to 
occupational exposures including: organic solvents, plastic monomers and additives, 
pesticides and metals. A study in Chinese patients with MSA that evaluated 
environmental exposures as well as potential biomarkers found that there was an increase 
in MSA in farmers. The study also revealed an association between disease severity and 
elevated serum homocysteine (Hcys) levels, suggesting Hcys as a potential biomarker for 
disease screening. 28 
Genetic components related to predisposition to MSA have received limited 
attention in terms of research. One case of probable familial MSA in which three sisters 
were all diagnosed with MSA-A suggests hereditary risk factors. It would be extremely 
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unlikely that three sisters spontaneously developed the same rare disease.1 There is 
also some evidence of genetic predisposition related to mutations in the COQ2 gene, 
especially in Japanese cohorts. The COQ2 gene codes for an enzyme that catalyzes the 
production CoQ10. Research has shown that in mice models CoQ10 has a 
neuroprotective effect against iron-induced apoptosis in brain cells.29 It is believed that 
the anti-oxidant properties of CoQ10 protect against the oxidative of iron accumulation. 
This decreased oxidative stress may reduce the mis-folding a-syn.   
 12 
 
Adapted from: Novel Therapeutic Approaches in Multiple system Atrophy by Kauffman et al.  
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Figure adapted from Towards transitional therapies for multiple system atrophy.  
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Adapted from Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of 
synucleinopathy.  
 
Existing research 
Unfortunately, due to the rare nature of MSA it has received less attention than the 
other synucleinopathies, PD and LBD. With a prevalence of 3.4-4.9 cases per 100,000 
population and estimated mean incidence of .6-.7 cases per 100,000 person years it is the 
least common of the synucleinopathies. Incidence of PD and DLB are: 4.5-21 per 
100,000 person years, respectively. The prevalence of PD 18-328 cases per 100,000 
person years while the prevalence of DLB is unknown.  Determining the underlying 
etiology of clinical dementia can be very challenging given the number of pathologies 
that lead to dementia (e.g. Lewy body, vascular, frontotemporal, Alzheimer’s .) Because 
of this difficulty, clinical diagnoses of DLB has poor sensitivity and specificity and there 
is no good evidence for the prevalence of the DLB. 26 
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In recent years, much has been learned about synucleinopathies, primarily 
through research of PD. With an improved understanding of the underlying 
pathology of these diseases research on potential treatments has also expanded. 
Most notably, recent safety and efficacy trials for Deferiprone, an iron chelator that 
crosses the blood brain barrier (BBB) and Nilotinib a tyrosine kinase inhibitor that 
reduces intracellular a-syn have proven to be potentially safe treatments of PD. 6,30 
Though these treatments have shown promise in ameliorating the symptoms of PD, 
and they have proven to be safe for patients, continued research is needed to further 
evaluate long term efficacy of these treatments.  Research regarding the role of iron 
dysregulation has also been instrumental in identifying the similarities and 
differences between synucleinopathies.4 These similarities of intracellular iron and 
a-syn accumulation between PD and MSA give hope that recent breakthroughs in PD 
treatment can give benefit to patients suffering from MSA as well.  
A study published by Visanji et al. in 2013 was aimed at elucidating the 
regional differences in iron and a-syn accumulation between PD and MSA. This 
study examined the brain tissue of patients with MSA and PD compared to normal 
control samples. 9 subjects total were examined; control (n = 3; 2 male, 1 female; 
ages 47, 63 and 78 years); PD (n = 3; 2 male, 1 female; ages 56, 73 and 79 years); 
MSA (n = 3; 2 male, 1 female; ages 46, 66 and 76 years).4 The samples were 
evaluated with Isothermal Remnant Magnetism, Western blotting and 
immunohistochemistry to calculate total iron, ferritin, ferriportin and transferrin, 
respectively.  This study uncovered several relationships between iron 
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dysregulation in PD and MSA including: elevated expression of Ferritin, increased 
iron concentration and ferritin bound iron in both MSA and PD, and alterations in 
ferriportin and transferrin receptor expression, and that regional iron status 
differentiates MSA from PD and from healthy controls. The data from this study is 
represented in the figures below. 
 
 
Figure 1:  
   
Fig. 1. Adapted from Iron Deficiency in Parkinsonism: Region-Specific Iron Dysregulation in Parkinson’s Disease and Multiple 
System Atrophy by Visanji et al 
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Figure 2:                                                                         Figure 3: 
  
Fig. 2. Adapted from Iron Deficiency in Parkinsonism: Region-Specific Iron Dysregulation in Parkinson’s Disease and Multiple 
System Atrophy by Visanji et al 
 
Fig. 3. Adapted from Iron Deficiency in Parkinsonism: Region-Specific Iron Dysregulation in Parkinson’s Disease and Multiple 
System Atrophy by Visanji et al 
  
 
While this study recognizes that the small number of samples utilized was a 
limitation, the findings strongly suggest that the differences in regional distribution 
of a-syn pathology may be a reflection of differences in iron dysregulation in the 
neurons and glia that are affected in PD and MSA. The symptoms that result from 
neurodegeneration in various synucleinopathies likely represent an end-point stage 
of the diseases natural progression resulting in the death and dysfunction of brain 
cells secondary to both iron and a-syn accumulation. 
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The findings of Visanji’s paper on regional iron dysregulation are corroborated in 
a study published by Wang et. al that evaluated the regional iron deposition patterns of 
PD and MSA-P using susceptibility weighted iron magnetic resonance imaging (SWI 
MR). SWI MR imaging is a newly described and highly sensitive imaging modality that 
can detect changes related to iron deposition in the brain. In this prospective study, fifty-
four age-matched healthy patients with PD (21 patients) and with MSA-P (10 patients) 
were recruited. All patients underwent brain imaging using 3D high resolution gradient 
echo SWI.7 Specifically, the regions of the brain that were evaluated for iron deposition 
were: substantia nigra (SN), Red nucleus (RN), Caudate nucleus (CN), globus pall idus 
(GP), Putamen, and the Thalamus (TH). Significant differences in iron deposition were 
found only in the SN and the Putamen. In the SN Significant differences were found in 
the SN (P < .05) of patients with IPD and MSA-P when compared with healthy controls. 
No statistical difference was found for patients with IPD versus MSA-P (P > .05) and in 
the Putamen iron concentrations were found to be higher for PD and MSA-P groups 
compared to healthy patients.  Iron deposition were significantly higher in patients with 
MSA-P compared to PD (P < .05). 7 
 The safety and efficacy of using the iron chelator Deferiprone was evaluated in a 
four year study by Giovanni et. al.  Six patients received Deferiprone solution at 
15 mg/kg PO bid. They were assessed by UPDRS, UDRS scales and blinded video 
rating, performed at baseline and every six months. Quantitative assessment of brain iron 
was performed with brain MRI at baseline and during follow up.  After 48 months of 
treatment and follow up evaluations of PD symptoms via UPDRS and UDRS clinical 
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rating scales indicated a stabilization in motor symptoms in 5/6 Pts. In the same subjects 
MRI evaluation showed reduced hypointensity in the globus pallidus (GP) that suggests 
reduction of the iron content of the GP. Arguably the most important finding in this trial 
was the evidence of halting the disease progression in two of the patients. Data was 
available for the patients 3 and 4 for four years prior to starting Deferiprone treatment. 
The figures below represent a drastic alteration in the progression of the disease course.  
  
Fig. 1.  Adapted from Iron Deficiency in Parkinsonism: Region-Specific Iron Dysregulation in Parkinson’s Disease and Multiple 
System Atrophy by Visanji et al.  
 
 The clinical stabilization observed in 5/6 of our patients suggests that 
Deferiprone exhibits long term safety and tolerability and may be a reasonable 
therapeutic option for the treatment of the neurological manifestations associated with 
iron accumulation and neurodegeneration. These results need to be confirmed by a large 
scale randomized clinical trial. 30 
 In addition to iron chelators like Deferiprone showing promise as potential 
treatments A tyrosine kinase inhibiting drug Nilotinib, which has been shown to reduce a-
syn accumulations in mouse models,31 and has recently undergone safety and efficacy 
testing in humans. A study published by Pagan et. al. aimed to demonstrate safety and 
tolerability of Nilotinib and to explore clinical outcomes in patients with PD and DLB. In 
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addition, potential CSF biomarkers were measured. In the study twelve subjects were 
randomized into two treatment arms including 150mg and 300 mg teat groups that 
received Nilotinib PO every day for 24 weeks with 12 weeks follow-up after stopping 
Nilotinib. Parameters that were measured included: electrocardiograms (EKGs), complete 
blood counts and metabolic panels, physical and neurological exams, including UPDRS 
scores were performed every two weeks for the first two months, and every month 
thereafter. A-syn ELISA was performed on CSF and plasma at baseline, 2 months, 
and 6 months.   
 Patients that participated in the open label Nilotinib trial experienced 
significant improvement in motor and non-motor symptoms. Patients’ cognitive 
performance was measured using MMSE and their autonomic symptoms were 
assessed with SCOPA-Cog. The scores of the MMSE and SCOPA-Cog improved by an 
average 3.85 points and 2 points, respectively. The participants’ motor symptoms 
were evaluated with UPDRS scores, which decreased throughout the trial in both the 
150mg and 300mg treatment arms. After 6 months of treatment an average 
decrease of 7 points in UPDRS was achieved in the 150 mg group while an 11.1 point 
reduction in UPRDS was achieved 300 mg groups. 
Improvement in the UPDRS scale is suggestive of the potential clinical benefit of 
Nilotinib. Unfortunately, after stopping treatment, these improvements  were 
reversed in participants in the follow up visit at 36 weeks.6 Many of the patients’ 
symptoms regressed back to their pre-trial baseline, despite restarting L-Dopa 
treatment regimen. 6 
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 Coenzyme Q10 (CoQ10) has also been evaluated as a potential treatment in 
neurodegenerative diseases with iron accumulation. A study performed Kooncumchoo et 
al demonstrated that both CoQ10 supplementation as well as deferoxamine treatment 
protected against iron induced neurodegeneration in mouse models. 29 This study 
evaluated gene-manipulated alpha-synuclein knockout (a-synko) mice, which are more 
resistant to oxidative damage, and normal control after exposure to FeSO4. Parameters 
that were measured in this study: metallothionein and glutathione, caspase-3 activation, 
NF-κB induction, and Bcl-2 expression.32 These markers were chosen as a means of 
measuring oxidative stress, mitochondrial damage and apoptosis.  The control mice were 
compared to two separate treatment arms including CoQ10 supplementation and 
Deferoxamine treatment.  
 This study found that FeSO4 exposure led to a dose-dependent increase ROS 
production, as well as statistically significant increases in caspase-3 and NF- κB 
expression and lipid peroxidation. This indicates that exposure to FeSO4 leads to iron-
induced oxidative stress and apoptotic cell death. This may be due to irons ability to 
synthesize toxic hydroxyl (OH) radicals and their contribution to oxidative stress that 
leads to lipid and protein damage and DNA fragmentation that leads to 
neurodegeneration.  
This study also found that the signs of oxidative damage and apoptosis were 
significantly decreased in the CoQ10 and Deferoxamine treatment arms. Deferoxamine 
lowers iron concentration and therefore decreases the overall oxidative stress caused by 
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and, it also significantly lowers iron-induced caspase activation which plays an essential 
part in the sequence of apoptosis. CoQ10 inhibits iron-induced apoptosis by augmenting 
antioxidant activity and by inhibiting pro-inflammatory cytokine activation. This study 
demonstrates the dose-dependent role of iron as it relates to neurodegeneration as well as 
the use of iron chelators and neuroprotective anti-oxidants as potential therapies for 
neurodegenerative diseases related to iron accumulation.  
 
Fig. 10. Adapted from CoenzymeQ10 neuroprotection iron-induced apoptosis in dopaminergic neurons by Kooncumchoo et al.  
 
 A review of potential novel therapies for MSA published by Palma and 
Kaufmann outlines potential therapeutic targets for treating MSA. Many of these 
drugs have shown promise in mouse models. Unfortunately, many of the beneficial 
interventions in mouse models for MSA have not transferred into beneficial 
treatments when tested in clinical trials. The therapies reviewed are divided into 
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four groups based on their mechanism for potential treatment. Those groups are: 
blocking a-syn arrival to the oligodendroglia, blocking a-syn aggregation, decreasing 
neuro inflammation and enhancing neuroprotection.  
 
Table 3: Therapies Targeting a-syn in MSA 
Mechanism of action Therapy Efficacy in MSA 
models 
Clinical 
Benefit 
Blocking a-syn arrival 
to oligodendrocytes 
Sertaline Yes Unknown 
Paroxetine Yes Yes 
a-syn antibodies Yes Unknown 
Inhibition of a-syn 
aggregation in 
oligodendrocytes 
Rifampicin Yes No 
Riluzole Yes No 
Lithium Yes No 
Enhancement of 
Neuroprotection 
Rasaglaine Yes No 
Growth Hormone Yes No 
Fluoxetine Yes Unknown 
Stem Cells Unknown Yes 
Neuro-anti-
inflammatory  
Minocycline Yes No 
IVIg Unknown Yes 
Table 3: Adapted from Novel therapeutic approaches in Multiple System Atrophy. Table outlines treatment models and their 
efficacy in MSA models either murine or cellular and their clinical benefits in human trials.  
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A few of the drugs worth highlighting in this review are paroxetine, stem 
cells and IVIG. Paroxetine is an SSRI used to treat depression. It has been 
demonstrated to provide some mild clinical improvement for MSA patients in a brief 
placebo-controlled clinical study. Twenty patients with suspected MSA were treated 
with paroxetine 30 mg for 2 weeks and showed a statistically significant 
improvement in motor performance. The Paroxetine treatment group showed a 
reduction in their UPDRS scores from baseline; (average change 3.27 p+0.089).33 
Although the improvements noted were clinically marginal the study was only 2 
weeks long. A longer and larger randomized clinical trial is needed to further 
evaluate the potential long-term efficacy of paroxetine. 33 
Mesenchymal stem cells have also recently arisen as a new and exciting 
therapeutic approach in MSA. Human stem cells present in adult bone marrow have 
the unique ability of differentiating into numerous cell types, including neurons.34 
Additionally, studies have shown that stem cells release a variety of cytokines and 
growth factors that have neuroprotective effects against progressive 
neurodegeneration of dopaminergic and striatal cells. Recently intravenous infusion 
of human stem cells have demonstrated benefit in human MSA models in an open-
label, non-blinded year-long study. This study demonstrated that arterial infusion of 
stem cells in 11 patients with MSA patients showed a significant improvement in 
orthostatic and cerebellar dysfunction sections of the UMSARS (total UMSARS 
p=0.047; UMSARS-II: p=0.008) , without any serious adverse effects. 34 
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Intravenous immunoglobulins (IVIg) have been used as an effective 
treatment for a variety diseases.  While it is most commonly used in auto-immune 
diseases it has also shown clinical benefit in neurodegenerative disorders, including 
multiple sclerosis. The mechanism of action for IVIg is not well defined. However, it 
is theorized that IVIg provides antibodies that potentially block inflammatory 
responses in the brain that protect the nervous system from immune-mediated 
damage. Another theory is that that the IVIg contains antibodies that are specific for 
a-syn that promote a-syn clearance from oligodendrocytes. In an open label trial 7 
patients with MSA received 6 monthly infusions of IVIg. The patients in this trial 
experienced significant improvements in the UMSARS-I scales (pre-treatment 
23.9±6.0 vs. post-treatment 19.0±5.9; p=0.01) and UMSARS-II (pre-treatment 
26.1±7.5 vs. post-treatment 23.3±7.3; p=0.025).  Further trials are required to 
evaluate for safety and to rule out any placebo effect. 35 
This review demonstrates the challenges of unraveling the pathophysiology 
of a disease in order to find pathways for targeted therapies to be used for 
treatment. It also highlights the complications of proving that targeted therapies 
that have been successful animal models can be effectively implemented in human 
clinical trials.  
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METHODS 
Study design 
This study will be a double-blind randomized clinical trial to evaluate the efficacy of 
Nilotinib and Deferiprone in the treatment of patients with MSA-P.  
 
Study population and recruitment 
The sample will include only patients over the age of 50 with diagnoses of probable and 
possible MSA-P, no other synucleinopathies will be included. Only patients in the mild to 
moderate symptoms will be included, patients with severe MSA will be excluded. 
Additional exclusionary criteria include: MSA-C and MSA-A classifications, dementia, 
patients with other iron-related medical issues, and patients on iron supplementation. 
Patients will be recruited from Neurology clinics of five academic medical centers in the 
area including: Boston Medical Center, Massachusetts General Hospital, Tufts Medical 
Center, Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center. Each 
group will consist of a minimum of 86 patients per treatment arm. This sample size was 
calculated using the mean and standard deviation of UMSARS II (motor) scales from the 
study by Novak et. al. which showed significant motor improvement of MSA patients 
treated IVIg. Parameters used: mu1=26, mu2=23, sigma=7, alpha = .05 and power = 0.8. 
36 
Treatment  
The patients will be divided into two intervention groups, the groups will be randomized 
1:1 using computer generated randomization. One group to be treated with Nilotinib 300 
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mg and a placebo while the other group will be treated with Nilotinib 300 mg and 
Deferiprone 15 mg. Both groups will receive 24 weeks of treatment followed by 24 
weeks of washout. During the intervention phase of this study patients’ will be evaluated 
in order to determine any significant difference between intervention groups. The follow-
up phase of the study will evaluate if the addition of Deferiprone will increase the amount 
of time before symptom regression.   
 
Study variables and measures 
The parameters that will be measured are the: Unified Multiple system atrophy rating 
scale (UMSARS) to assess motor function of the patients1, Scales for Outcomes in 
Parkinson’s disease – Autonomic (SCOPA) to assess autonomic dysfunction, and the 
Montreal Cognitive Assessment (MOCA) to assess for Dementia.  These scales as well as 
vital signs and a full neurological exam will be evaluated every four weeks throughout 
the intervention and follow-up phases of the study. Patients in both groups will also 
receive EKG at each clinic visit to monitor for QTc prolongation that can be a side effect 
of Nilotinib.37 Imaging and laboratory data will include brain MRI scans, CSF a-syn and 
iron panel studies, Comprehensive Metabolic Panel (CMP) and Complete Blood Count 
(CBC). Imaging and laboratory data will be assessed at the onset of the study (week 0) at 
the end of the intervention phase (week 24) and at the end of the follow-up phase (week 
48).  
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Data collection 
Data will be collected by Neurologists with the help of a research assistant at each of the 
monthly patient visits.  Utilizing standardized rating scales, Neurologists will complete 
UPDRS, UMSARS, SCOPA, and MOCA.  The data from the neurologists exam will be 
entered into Microsoft excel by the research assistant. At weeks 0, 24, and 48 Patients 
will get brain scans using SWI MR to evaluate for neuronal iron accumulation and 
lumbar punctures to evaluate iron levels in the CSF. The levels of iron and a-syn in the 
CSF and SWI MR iron levels will also be entered into excel to assess for any significant 
changes throughout the course of the trial. 
  
Data analysis 
Data collected throughout this study will be analyzed using an analysis of variance 
(ANOVA) to assess for changes in motor function measured by the UMSARS and 
UPDRS III. Brain iron levels on SWI MR, and CSF levels of iron and a-syn. SWI MR 
from weeks 0, 24, and 48 will be evaluated for any significant changes in iron deposition 
throughout the trial.  
Interrater variability is a potential confounder in any study that relies on physical 
exam rating scales like the UMSARS and UPDRS. Fortunately, both the UMSARS and 
UPDRS have shown to have excellent interrater agreement.1 With the only exception 
being ocular motor dysfunction examination, which reported moderate interrater 
agreement.38  Because there is limited data pertaining to the use of Deferiprone or 
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Nilotinib in the treatment of MSA-P, it may be difficult to assign any benefit to one drug, 
specifically, in the event that both treatment arms show similar results.   
 
Timeline and resources 
 
Table 3: Timeline 
January 2017 IRB Submission and Approval 
September 2017 Patient Recruitment 
January 2018-January 2019 Treatment Intervention and Washout 
Phases 
March 2019 Data Analysis 
May 2019 Submission for Peer Review 
 
Institutional Review Board 
The study will be submitted for full IRB review protocol under INSPIR II criteria of the 
Boston University Medical Campus as well as the corresponding IRBs of the other four 
participating Medical Institutions.  
Budget line items: Administrative Support  
• Clerical (Wages)  
• Data entry  
• Statistical consulting  
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Supplies and Expenses  
• MRI machine 
• Lumbar Puncture kits 
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CONCLUSION 
Discussion 
There are some notable limitations to the design of this study. Most notably is the limited 
evidence of the use of either Nilotinib or Deferiprone in the treatment of MSA-P. There 
has never been a trial of either of these drugs in the treatment of MSA-P in human 
patients. However, there is evidence of the efficacy of Nilotinib and Deferiprone in 
removing a-syn and iron, respectively, from neurons in patients suffering from PD.  
There has also been several papers that demonstrate the similar pathologies of PD and 
MSA-P. Both SWI MR and histopathological sampling of brain tissue have shown 
unique regional patterns in the deposition of iron in PD and MSA-P and deposition of 
iron has been associated with deposition of a-syn.  
 The rarity of MSA-P poses yet another potential limitation may be recruiting a 
large enough patient population to obtain statistical significance. Additional Medical 
centers and Neurology clinics may need to be included if patient recruitment is 
insufficient.   
 
Summary 
MSA-P and the other forms of MSA still have no available treatment, a major contributor 
to the diseases poor prognosis. Many of the recent clinical trials of potential therapies 
have been unsuccessful. Taking advantage of the new evidence that exposes the 
similarities of MSA-P and PD can create a different approach to treatment. There is a 
growing body of evidence that correlates iron deposition to synucleinopathies, but there 
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has not yet been a trial with medications that can clear both a-syn and iron from brain 
cells. The proposal of this study will use Nilotinib and Deferiprone concomitantly in 
hopes that they may have a synergistic effect in terms of improving the motor and non-
motor symptoms associated with MSA-P.  
 
Clinical and/or public health significance 
The natural history of the disease and current lack of any treatment modality for MSA-P 
leads to a very poor prognosis and a short life expectancy of only 6.2-9.5 years. Upon 
diagnosis of MSA-P most patients experience rapid progression of symptoms 
precipitating a rapid decline in health related quality of life. Patients who carry a 
diagnoses of MSA-P not only suffer from the debilitating motor and non-motor 
symptoms of the disease but many will also develop severe depression.  This trial aims to 
establish a new standard of care by implementing evidence based treatment for MSA-P 
that could potentially improve life expectancy as well as quality of life in this patient 
population.  
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APPENDIX 
UNIFIED PARKINSON'S DISEASE RATING SCALE 
Fahn S, Elton R, Members of the UPDRS Development Committee. 
In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. 
Recent Developments in Parkinson's Disease, Vol 2. Florham Park, NJ. Macmillan 
Health Care Information 1987, pp 15 3-163, 293-304 
I. MENTATION, BEHAVIOR AND MOOD 
1. Intellectual Impairment 
0 = None. 
1 = Mild. Consistent forgetfulness with partial recollection of events and no other 
difficulties. 
2 = Moderate memory loss, with disorientation and moderate difficulty handling complex 
problems. Mild but definite 
impairment of function at home with need of occasional prompting. 
3 = Severe memory loss with disorientation for time and often to place. Severe 
impairment in handling problems. 
4 = Severe memory loss with orientation preserved to person only. Unable to make 
judgements or solve problems. 
Requires much help with personal care. Cannot be left alone at all. 
2. Thought Disorder (Due to dementia or drug intoxication) 
0 = None. 
1 = Vivid dreaming. 
2 = "Benign" hallucinations with insight retained. 
3 = Occasional to frequent hallucinations or delusions; without insight; could interfere 
with daily activities. 
4 = Persistent hallucinations, delusions, or florid psychosis. Not able to care for self. 
3. Depression 
1 = Periods of sadness or guilt greater than normal, never sustained for days or weeks. 
2 = Sustained depression (1 week or more). 
3 = Sustained depression with vegetative symptoms (insomnia, anorexia, weight loss, 
loss of interest). 
4 = Sustained depression with vegetative symptoms and suicidal thoughts or intent. 
4. Motivation/Initiative 
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0 = Normal. 
1 = Less assertive than usual; more passive. 
2 = Loss of initiative or disinterest in elective (non-routine) activities. 
3 = Loss of initiative or disinterest in day to day (routine) activities. 
4 = Withdrawn, complete loss of motivation. 
II. ACTIVITIES OF DAILY LIVING (for both "on" and "off") 
5. Speech 
0 = Normal. 
1 = Mildly affected. No difficulty being understood. 
2 = Moderately affected. Sometimes asked to repeat statements. 
3 = Severely affected. Frequently asked to repeat statements. 
4 = Unintelligible most of the time. 
6. Salivation 
0 = Normal. 
1 = Slight but definite excess of saliva in mouth; may have nighttime drooling. 
2 = Moderately excessive saliva; may have minimal drooling. 
3 = Marked excess of saliva with some drooling. 
4 = Marked drooling, requires constant tissue or handkerchief. 
7. Swallowing 
0 = Normal. 
1 = Rare choking. 
2 = Occasional choking. 
3 = Requires soft food. 
4 = Requires NG tube or gastrostomy feeding. 
8. Handwriting 
0 = Normal. 
1 = Slightly slow or small. 
2 = Moderately slow or small; all words are legible. 
3 = Severely affected; not all words are legible. 
4 = The majority of words are not legible. 
9. Cutting food and handling utensils 
0 = Normal. 
1 = Somewhat slow and clumsy, but no help needed. 
 35 
2 = Can cut most foods, although clumsy and slow; some help needed. 
3 = Food must be cut by someone, but can still feed slowly. 
4 = Needs to be fed. 
10. Dressing 
0 = Normal. 
1 = Somewhat slow, but no help needed. 
2 = Occasional assistance with buttoning, getting arms in sleeves. 
3 = Considerable help required, but can do some things alone. 
4 = Helpless. 
11. Hygiene 
0 = Normal. 
1 = Somewhat slow, but no help needed. 
2 = Needs help to shower or bathe; or very slow in hygienic care. 
3 = Requires assistance for washing, brushing teeth, combing hair, going to bathroom. 
4 = Foley catheter or other mechanical aids. 
12. Turning in bed and adjusting bed clothes 
0 = Normal. 
1 = Somewhat slow and clumsy, but no help needed. 
2 = Can turn alone or adjust sheets, but with great difficulty. 
3 = Can initiate, but not turn or adjust sheets alone. 
4 = Helpless. 
13. Falling (unrelated to freezing) 
0 = None. 
1 = Rare falling. 
2 = Occasionally falls, less than once per day. 
3 = Falls an average of once daily. 
4 = Falls more than once daily. 
14. Freezing when walking 
0 = None. 
1 = Rare freezing when walking; may have start hesitation. 
2 = Occasional freezing when walking. 
3 = Frequent freezing. Occasionally falls from freezing. 
4 = Frequent falls from freezing. 
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15. Walking 
0 = Normal. 
1 = Mild difficulty. May not swing arms or may tend to drag leg. 
2 = Moderate difficulty, but requires little or no assistance. 
3 = Severe disturbance of walking, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
16. Tremor (Symptomatic complaint of tremor in any part of body.) 
0 = Absent. 
1 = Slight and infrequently present. 
2 = Moderate; bothersome to patient. 
3 = Severe; interferes with many activities. 
4 = Marked; interferes with most activities. 
17. Sensory complaints related to Parkinsonism 
0 = None. 
1 = Occasionally has numbness, tingling, or mild aching. 
2 = Frequently has numbness, tingling, or aching; not distressing. 
3 = Frequent painful sensations. 
4 = Excruciating pain. 
III. MOTOR EXAMINATION 
18. Speech 
0 = Normal. 
1 = Slight loss of expression, diction and/or volume. 
2 = Monotone, slurred but understandable; moderately impaired. 
3 = Marked impairment, difficult to understand. 
4 = Unintelligible. 
19. Facial Expression 
0 = Normal. 
1 = Minimal hypomimia, could be normal "Poker Face". 
2 = Slight but definitely abnormal diminution of facial expression. 
3 = Moderate hypomimia; lips parted some of the time. 
4 = Masked or fixed facies with severe or complete loss of facial expression; lips parted 
1/4 inch or more. 
20. Tremor at rest (head, upper and lower extremities) 
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0 = Absent. 
1 = Slight and infrequently present. 
2 = Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently 
present. 
3 = Moderate in amplitude and present most of the time. 
4 = Marked in amplitude and present most of the time. 
21. Action or Postural Tremor of hands 
0 = Absent. 
1 = Slight; present with action. 
2 = Moderate in amplitude, present with action. 
3 = Moderate in amplitude with posture holding as well as action. 
4 = Marked in amplitude; interferes with feeding. 
22. Rigidity (Judged on passive movement of major joints with patient relaxed in sitting 
position. Cog wheeling to be ignored.) 
0 = Absent. 
1 = Slight or detectable only when activated by mirror or other movements. 
2 = Mild to moderate. 
3 = Marked, but full range of motion easily achieved. 
4 = Severe, range of motion achieved with difficulty. 
23. Finger Taps (Patient taps thumb with index finger in rapid succession.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in 
movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement. 
4 = Can barely perform the task. 
24. Hand Movements (Patient opens and closes hands in rapid succession.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in 
movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement. 
4 = Can barely perform the task. 
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25. Rapid Alternating Movements of Hands (Pronation-supination movements of hands, 
vertically and horizontally, with as large an amplitude as possible, both hands 
simultaneously.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in 
movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement. 
4 = Can barely perform the task. 
26. Leg Agility (Patient taps heel on the ground in rapid succession picking up entire leg. 
Amplitude should be at least 3 inches.) 
0 = Normal. 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in 
movement. 
3 = Severely impaired. Frequent hesitation in initiating movements or arrests in ongoing 
movement. 
4 = Can barely perform the task. 
27. Arising from Chair (Patient attempts to rise from a straight-backed chair, with arms 
folded across chest.) 
0 = Normal. 
1 = Slow; or may need more than one attempt. 
2 = Pushes self-up from arms of seat. 
3 = Tends to fall back and may have to try more than one time, but can get up without 
help. 
4 = Unable to arise without help. 
28. Posture 
0 = Normal erect. 
1 = Not quite erect, slightly stooped posture; could be normal for older person. 
2 = Moderately stooped posture, definitely abnormal; can be slightly leaning to one side. 
3 = Severely stooped posture with kyphosis; can be moderately leaning to one side. 
4 = Marked flexion with extreme abnormality of posture. 
29. Gait 
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0 = Normal. 
1 = Walks slowly, may shuffle with short steps, but no festination (hastening steps) or 
propulsion. 
2 = Walks with difficulty, but requires little or no assistance; may have some festination, 
short steps, or propulsion. 
3 = Severe disturbance of gait, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
30. Postural Stability (Response to sudden, strong posterior displacement produced by 
pull on shoulders while patient erect with eyes open and feet slightly apart. Patient is 
prepared.) 
0 = Normal. 
1 = Retropulsion, but recovers unaided. 
2 = Absence of postural response; would fall if not caught by examiner. 
3 = Very unstable, tends to lose balance spontaneously. 
4 = Unable to stand without assistance. 
31. Body Bradykinesia and Hypokinesia (Combining slowness, hesitancy, decreased arm 
swing, small amplitude, and poverty of movement in general.) 
0 = None. 
1 = Minimal slowness, giving movement a deliberate character; could be normal for some 
persons. Possibly reduced amplitude. 
2 = Mild degree of slowness and poverty of movement which is definitely abnormal. 
Alternatively, some reduced amplitude. 
3 = Moderate slowness, poverty or small amplitude of movement. 
4 = Marked slowness, poverty or small amplitude of movement. 
IV. COMPLICATIONS OF THERAPY (In the past week) 
A. DYSKINESIAS 
32. Duration: What proportion of the waking day are dyskinesias present? (Historical 
information.) 
0 = None 
1 = 1-25% of day. 
2 = 26-50% of day. 
3 = 51-75% of day. 
4 = 76-100% of day. 
33. Disability: How disabling are the dyskinesias? (Historical information; may be 
modified by office examination.) 
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0 = Not disabling. 
1 = Mildly disabling. 
2 = Moderately disabling. 
3 = Severely disabling. 
4 = Completely disabled. 
34. Painful Dyskinesias: How painful are the dyskinesias? 
0 = No painful dyskinesias. 
1 = Slight. 
2 = Moderate. 
3 = Severe. 
4 = Marked. 
35. Presence of Early Morning Dystonia (Historical information.) 
0 = No 
1 = Yes 
B. CLINICAL FLUCTUATIONS 
36. Are "off" periods predictable? 
0 = No 
1 = Yes 
37. Are "off" periods unpredictable? 
0 = No 
1 = Yes 
38. Do "off" periods come on suddenly, within a few seconds? 
0 = No 
1 = Yes 
39. What proportion of the waking day is the patient "off" on average? 
0 = None 
1 = 1-25% of day. 
2 = 26-50% of day. 
3 = 51-75% of day. 
4 = 76-100% of day. 
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C. OTHER COMPLICATIONS 
40. Does the patient have anorexia, nausea, or vomiting? 
0 = No 
1 = Yes 
41. Any sleep disturbances, such as insomnia or hypersomnolence? 
0 = No 
1 = Yes 
42. Does the patient have symptomatic orthostasis? (Record the patient's blood pressure, 
height and weight on the scoring form) 
0 = No 
1 = Yes 
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APPENDIX B 
UNIFIED MSA RATING SCALE (UMSARS) Part I: Historical Review 
Rate the average functional situation for the past 2 weeks (unless specified) according to 
the patient and caregiver interview. Indicate the score that best fits with the patient status. 
Rate the function independently from the nature of the signs. 
1. Speech 
0 = Not affected.                                                                                                                    
1 = Mildly affected. No difficulties being understood.                                                          
2 = Moderately affected. Sometimes (less than half of the time) asked to repeat 
statements.  
3 = Severely affected. Frequently (more than half of the time) asked to repeat statements. 
4 =Unintelligible most of the time.  
2. Swallowing 
0 = Normal.  
1 = Mild impairment. Choking less than once a week.                                                            
2 = Moderate impairment. Occasional food aspiration with choking more than once a 
week.                                                                                                                                     
3 = Marked impairment. Frequent food aspiration.                                                                 
4 = Nasogastric tube or gastrostomy feeding.  
3. Handwriting 
0 = Normal                                                                                                                               
1 = Mildly impaired, all words are legible.                                                                              
2 = Moderately impaired, up to half of the words are not legible.                                            
3 = Markedly impaired, the majority of words are not legible.                                               
4 = Unable to write.  
4. Cutting food and handling utensils 
0 = Normal.                                                                                                                             
1 = Somewhat slow and/or clumsy, but no help needed.                                                         
2 = Can cut most foods, although clumsy and slow; some help needed.                                           
3 = Food must be cut by someone, but can still feed slowly.                                                   
4 = Needs to be fed.  
5. Dressing 
0 = Normal.                                                                                                                               
1 = Somewhat slow and/or clumsy, but no help needed.                                                          
2 = Occasional assistance with buttoning, getting arms in sleeves.                                              
3 = Considerable help required, but can do some things alone.                                               
4 = Completely helpless.  
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6. Hygiene 
0 = Normal.                                                                                                                                      
1 = Somewhat slow and/or clumsy, but no help needed.                                                                           
2 = Needs help to shower or bathe; or very slow in hygienic care.                                                         
3 = Requires assistance for washing, brushing teeth, combing hair, using the toilet.                              
4 = Completely helpless. 
7. Walking 
0 = Normal.                                                                                                                                 
1 = Mildly impaired. No assistance needed. No walking aid required (except for unrelated 
disorders).                                                                                                                               
2 = Moderately impaired. Assistance and/or walking aid needed occasionally.                                   
3 = Severely impaired. Assistance and/or walking aid needed frequently.                                                   
4 = Cannot walk at all even with assistance.  
8. Falling (rate the past month) 
0 = None.                                                                                                                                                  
1 = Rare falling (less than once a month).                                                                                               
2 = Occasional falling (less than once a week).                                                                                             
3 = Falls more than once a week. 4 Falls at least once a day (if the patient cannot walk at 
all, rate 4).  
9. Orthostatic symptoms 
0 = No orthostatic symptoms.*                                                                                                                  
1 = Orthostatic symptoms are infrequent and do not restrict activities of daily living.                             
2 = Frequent orthostatic symptoms developing at least once a week. Some limitation in 
activities of daily living.                                                                                                                       
3 = Orthostatic symptoms develop on most occasions. Able to stand 1 min on most 
occasions. Limitation in most of activities of daily living.                                                                    
4 = Symptoms consistently develop on orthostasis. Able to stand 1 min on most 
occasions. Syncope/presyncope is common if patient attempts to stand. 
                  *Syncope, dizziness, visual disturbances or neck pain, relieved on lying flat.  
10. Urinary function* 
0 = Normal.                                                                                                                                                 
1 = Urgency and/or frequency, no drug treatment required.                                                                         
2 = Urgency and/or frequency, drug treatment required.                                                                                  
3 = Urge incontinence and/or incomplete bladder emptying needing intermittent 
catheterization.                                                                                                                                           
4 = Incontinence needing indwelling catheter. 
*Urinary symptoms should not be due to other causes.  
11. Sexual function 
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0 = No problems.                                                                                                                                             
1 = Minor impairment compared to healthy days.                                                                                            
2 = Moderate impairment compared to healthy days.                                                                                          
3 = Severe impairment compared to healthy days.                                                                                         
4 = No sexual activity possible.  
12. Bowel function 
0 = No change in pattern of bowel function from previous pattern.                                                               
1 = Occasional constipation but no medication needed.                                                                                 
2 = Frequent constipation requiring use of laxatives.                                                                               
3 = Chronic constipation requiring use of laxatives and enemas.                                                                                    
4 = Cannot have a spontaneous bowel movement.  
 
Total score Part I: 
 
Part II: Motor Examination Scale  
Always rate the worst affected limb. 
1. Facial expression 
0 = Normal.                                                                                                                                                    
1 = Minimal hypomimia, could be normal (“Poker face”).                                                                               
2 = Slight but definitely abnormal diminution of facial expression.                                                              
3 = Moderate hypomimia; lips parted some of the time.                                                                                   
4 = Masked or fixed facies with severe or complete loss of facial expression, lips parted 
0.25 inch or more.  
2. Speech 
The patient is asked to repeat several times a standard sentence.                                                                      
0 = Normal.                                                                                                                                                  
1 = Mildly slow, slurred, and/or dysphonic. No need to repeat statements.                                                           
2 = Moderately slow, slurred, and/or dysphonic. Sometimes asked to repeat statements.                       
3 = Severely slow, slurred, and/or dysphonic. Frequently asked to repeat statements.                          
4 = Unintelligible. 
3. Ocular motor dysfunction 
Eye movements are examined by asking the subject to follow slow horizontal finger 
movements of the examiner, to look laterally at the finger at different positions, and to 
perform saccades between two fingers, each held at an eccentric position of 
approximately 30°. The examiner assesses the following abnormal signs:                                        
(1) broken-up smooth pursuit,                                                                                                             
(2) gaze-evoked nystagmus at an eye position of more than 45 degrees,                                              
(3) gaze-evoked nystagmus at an eye position of less than 45 degrees,                                                       
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(4) saccadic hypermetria. Sign 3 suggests that there are at least two abnormal ocular 
motor signs, because Sign 2 is also present. 
0 = None.                                                                                                                                        
1 = One abnormal ocular motor sign.                                                                                                       
2 = Two abnormal ocular motor signs.                                                                                               
3 = Three abnormal ocular motor signs.                                                                                                     
4 = Four abnormal ocular motor signs.         
                                                                                                                                                                  
4. Tremor at rest (rate the most affected limb) 
0 = Absent.                                                                                                                                                     
1 = Slight and infrequently present.                                                                                                             
2 = Mild in amplitude and persistent. Or moderate in amplitude, but only intermittently 
present.                                                                                                                                                  
3 = Moderate in amplitude and present most of the time,                                                                          
4 = Marked in amplitude and present most of the time, 5. Action tremor 
Assess postural tremor of outstretched arms                                                                                      
(A) and action tremor on finger pointing                                                                                              
(B). Rate maximal tremor severity in Task A and/or B (whichever is worse), and rate the 
most affected limb. 
0 = Absent.                                                                                                                                                  
1 = Slight tremor of small amplitude (A). No interference with finger pointing (B).                                               
2 = Moderate amplitude (A). Some interference with finger pointing (B).                                               
3 = Marked amplitude (A). Marked interference with finger pointing (B).                                                 
4 = Severe amplitude (A). Finger pointing impossible (B). 6. Increased tone (rate the 
most affected limb) 
Judged on passive movement of major joints with patient relaxed in sitting position; 
ignore cog wheeling.                                                                                                                                
0 = Absent.                                                                                                                                                
1 = Slight or detectable only when activated by mirror or other movements.                                              
2 = Mild to moderate.                                                                                                                                 
3 = Marked, but full range of motion easily achieved.                                                                                     
4 = Severe, range of motion achieved with difficulty. 7. Rapid alternating movements of 
hands 
Pro-supination movements of hands, vertically or horizontally, with as large an 
amplitude as possible, each hand separately, rate the worst affected limb. Note that 
impaired performance on this task can be caused by bradykinesia and/or cerebellar 
incoordination. Rate functional performance regardless of underlying motor disorder. 
0 = Normal.                                                                                                                                                  
1 = Mildly impaired.                                                                                                                                   
2 = Moderately impaired.                                                                                                                                 
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3 = Severely impaired.                                                                                                                                   
4 = Can barely perform the task. 8. Finger taps 
Patient taps thumb with index finger in rapid succession with widest amplitude 
possible, each hand at least 15 to 20 seconds. Rate the worst affected limb. Note that 
impaired performance on this task can be caused by bradykinesia and/or cerebellar 
incoordination. Rate functional performance regardless of underlying motor disorder. 
0 = Normal.                                                                                                                                                   
1 = Mildly impaired.                                                                                                                                                        
2 = Moderately impaired.                                                                                                                             
3 = Severely impaired.                                                                                                                                                         
4 = Can barely perform the task. 9. Leg agility 
Patient is sitting and taps heel on ground in rapid succession, picking up entire leg. 
Amplitude should be approximately 10 cm, rate the worst affected leg. Note that 
impaired performance on this task can be caused by bradykinesia and/or cerebellar 
incoordination. Rate functional performance, regardless of underlying motor disorder. 
0 = Normal.                                                                                                                                                        
1 = Mildly impaired.                                                                                                                                     
2 = Moderately impaired.                                                                                                                                 
3 = Severely impaired.                                                                                                                                    
4 = Can barely perform the task. 10. Heel-knee-shin test 
The patient is requested to raise one leg and place the heel on the knee, and then slide 
the heel down the anterior tibial surface of the resting leg toward the ankle. On reaching 
the ankle joint, the leg is again raised in the air to a height of approximately 40 cm and 
the action is repeated. At least three movements of each limb must be performed for 
proper assessment. Rate the worst affected limb. 
0 = Normal.                                                                                                                                                    
1 = Mildly dysmetric and ataxic.                                                                                                                 
2 = Moderately dysmetric and ataxic.                                                                                                                  
3 = Severely dysmetric and ataxic.                                                                                                                   
4 = Can barely perform the task. 
11. Arising from chair 
Patient attempts to arise from a straight-back wood or metal chair with arms folded across 
chest.  
0 = Normal.                                                                                                                                               
1 = Clumsy, or may need more than one attempt.                                                                                            
2 = Pushes self-up from arms of seat.                                                                                                              
3 = Tends to fall back and may have to try more than once but can get up without help.                         
4 = Unable to arise without help.  
12. Posture 
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0 = Normal.                                                                                                                                                   
1 = Not quite erect, slightly stooped posture; could be normal for older person.                                             
2 = Moderately stooped posture, definitely abnormal; can be slightly leaning to one side.                         
3 = Severely stooped posture with kyphosis; can be moderately leaning to one side.                              
4 = Marked flexion with extreme abnormality of posture.  
13. Body sway 
Rate spontaneous body sway and response to sudden, strong posterior displacement 
produced by pull on shoulder while patient erect with eyes open and feet slightly apart. 
Patient has to be warned. 
0 = Normal.                                                                                                                                                  
1 = Slight body sway and/or retropulsion with unaided recovery.                                                               
2 = Moderate body sway and/or deficient postural response; might fall if not caught by 
examiner.                                                                                                                                                        
3 = Severe body sway. Very unstable. Tends to lose balance spontaneously.                                                    
4 = Unable to stand without assistance.  
14. Gait 
0 = Normal.                                                                                                                                               
1 = Mildly impaired.                                                                                                                                    
2 = Moderately impaired. Walks with difficulty, but requires little or no assistance.                                             
3 = Severely impaired. Requires assistance.                                                                                                
4 = Cannot walk at all, even with assistance.  
 
Total score Part II: 
 
Part III: Autonomic Examination 
Supine blood pressure and heart rate are measured after 2 minutes of rest and again after 
2 minutes of standing. Orthostatic symptoms may include lightheadedness, dizziness, 
blurred vision, weakness, fatigue, cognitive impairment, nausea, palpitations, 
tremulousness, headache, neck and “coat-hanger” ache. 
Systolic blood pressure 
Supine Standing (2 minutes) Unable to record Diastolic blood pressure                                        
Supine Standing (2 minutes) Unable to record Heart rate                                                           
Supine Standing (2 minutes) Unable to record Orthostatic symptoms 
Yes No 
Part IV: Global Disability Scale  
1. Completely independent. Able to do all chores with minimal difficulty or impairment. 
Essentially normal. Unaware of any difficulty.  
2. Not completely independent. Needs help with some chores.  
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3. More dependent. Help with half of chores. Spends a large part of the day with chores. 
4. Very dependent. Now and then does a few chores alone or begins alone. Much help 
needed. 5. Totally dependent and helpless. Bedridden. 
Movement Disorders, Vol. 19, No. 12, 2004  
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APPENDIX C 
SCOPA Questionnaire 
Answers were based upon symptoms during the previous month. 
Patients answered “yes” or “no” to questions related to medicine taking. 
Patients could answer “never, or none” (0 point), “sometimes = 1–9 times” (1 
point),“regular = 10-09 times” (2 points), and “frequent = >20 times” (3 points) 
The questions: 
1 Have you had any difficulty in swallowing food or experienced laryngospasm? 
2. Have you ever spontaneously drooled? 
3. Have you ever been choked because food has stuck in your throat? 
4. Have you ever felt becoming quickly full while eating? (even a small amount) 
5. Have you ever experienced constipation? (people in normal condition can move the 
bowels twice or less per week at times) ____times/week 
6. Is it very difficult for you when you have a bowl movement? 
7. Have you ever spontaneously had a bowl movement? 
8. Do you have difficulties holding urine? 
9. Have your ever spontaneously urinated? 
10. Have you ever felt a refreshed feeling upon urinating? 
11. Has your urination stream become weak? 
12. Have you ever urinated again within 2 h after having urinated? 
13. Have you ever urinated at night? 
14. Have you ever felt dizzy upon standing up from sitting down, had blurred vision, or 
your head becoming cloudy? 
15. Have you ever felt dizzy upon standing after sitting down? 
16. Have you fainted during the last 6 months? 
17. Have you ever profusely sweated during daytime? 
18. Have you ever profusely sweated during nighttime? 
19. Have you ever felt that a bright light was unbearably bright? 
20. Have you ever experienced unbearable cold? 
21. Have you ever experienced unbearable heat? 
For males only: 
22. Have you ever experienced erectile dysfunction? 
23. Have you ever experienced ejaculation difficulties? 
 23a. Have you taken medicine for item 22, 23? (Y/N) 
For females only: 
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SCOPA Questionnaire 
Answers were based upon symptoms during the previous month. 
Patients answered “yes” or “no” to questions related to medicine taking. 
Patients could answer “never, or none” (0 point), “sometimes = 1–9 times” (1 
point),“regular = 10-09 times” (2 points), and “frequent = >20 times” (3 points) 
24. Have you ever experienced vaginal dryness during sexual intercourse? 
25. Have you ever experienced difficulties in reaching orgasm? 
26. Have you taken medicine for? (Y/N) 
  a. constipation; b. urination difficulty; c. blood pressure; d. other symptoms. 
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APPENDIX D 
MOCA QUSTIONAIRRE.  
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